Valeant Pharmaceuticals 2015: Roll-Up Strategy & The Philidor Channel│EP155 T1  episode artwork

EPISODE · Jul 24, 2026 · 10 MIN

Valeant Pharmaceuticals 2015: Roll-Up Strategy & The Philidor Channel│EP155 T1

from Financial Forensics: Autopsy Files · host Sergio Stieben

In early 2015, Valeant Pharmaceuticals reported that volume was driving earnings, yet internal quarterly data revealed that roughly 80% of growth stemmed from price increases. Shortly after peaking at a $90 billion market capitalization, Valeant’s stock collapsed by 97%. This financial autopsy dissects the mechanics of Valeant’s aggressive M&A roll-up model and the hidden distribution network that sustained it. We trace how Valeant acquired existing drug portfolios, cut R&D spending, and implemented price hikes of over 500%. We uncover the role of Philidor Rx Services—a mail-order specialty pharmacy that Valeant secretly controlled through an undisclosed option agreement. Discover how Philidor bypassed insurer utilization reviews, altered prescriptions to "dispense as written," and resubmitted claims under alternate pharmacy entities to force reimbursement. 🔴 Every corporate failure leaves behind a pattern — and every good decision leaves one too.This episode is part of Financial Forensics Labs — two shows, one forensic methodology: The Due Diligence Files traces how institutions collapse, The Signal Files traces how the good calls get made. Built from primary-record research by a 15-year capital markets professional.Get to know the framework, the other show, and the tools built from it — all in one place.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Explore Financial Forensics Labs →⁠⁠Valeant Pharmaceuticals financial autopsy, Philidor Rx Services specialty pharmacy scandal, Michael Pearson roll up M&A strategy, pharmaceutical price gouging case study, specialty pharma channel stuffing, undisclosed related party transactions, generic drug substitution bypass, pharmacy benefit manager payer rejection, short seller Citron Research report, drug price increase organic growth vs price, high yield debt leverage pharma roll up, Bausch Health SEC accounting settlement, B2B captive distribution channel risk, Wall Street pharma accounting collapse The Due Diligence Files— Every collapse has a pattern. We dissect it.

Episode metadata supplied by the publisher feed · Published Jul 24, 2026

Embed this episode

NOW PLAYING

Valeant Pharmaceuticals 2015: Roll-Up Strategy & The Philidor Channel│EP155 T1

0:00 10:52

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Financial Forensics: Autopsy Files?

This episode is 10 minutes long.

When was this Financial Forensics: Autopsy Files episode published?

This episode was published on July 24, 2026.

Can I download this Financial Forensics: Autopsy Files episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!